Therefore, based on existing literature, we synthesized the specific inhibitor 3-[(2S)-1-[(3R)-3-(2-Chlorophenyl)-2-(2-fluorophenyl) pyrazolidin-1-yl]-1-oxopropa n-2-yl]-1-(adamantan-2-yl)urea, referred to as NR2 for ease of description, which has been reported to specifically inhibit the function of NLN in research on acute myeloid leukemia (AML) [10,26]. The gene discussed is NLN; the disease is acute myeloid leukemia.